Key Points
In a significant move, pharma giant AstraZeneca has recalled its Covid-19 vaccine, made in collaboration with Oxford University, worldwide, months after admitting in the UK court about its potential rare blood clot side effect...
The company voluntarily withdrew its marketing authorisation of its Covid vaccine, sold as Covishield in India and Vaxzevria in Europe..
Credited for saving more than six million lives, AstraZeneca accepted, in a legal document submitted to the High Court in February, that its Covid vaccine can, in very rare cases, cause TTS, the report said.. Thrombotic Thrombocytopenic Syndrome (TTS) is a rare side effect that can cause people to have blood clots and a low blood platelet count, linked to at least 81 deaths in the UK as well as hundreds of serious injuries...
However, AstraZeneca noted that the vaccine is being withdrawn for commercial reasons and is not linked to the court case, and that the timing was pure coincidence...
The company noted that it will collaborate with global regulatory authorities to initiate marketing authorisation withdrawals for Vaxzevria, where no future commercial demand for the vaccine is expected...
You might be interested in
AstraZeneca withdraws Covid vaccine worldwide, cites commercial reasons
14, May, 24AstraZeneca has withdrawn the Covid vaccine as it has been superseded by updated ones that fight new variants & is no longer being made, supplied.
Explained: Why AstraZeneca has decided to withdraw its Covid vaccine globally
08, May, 24AstraZeneca had recently admitted in court documents that its vaccine against Covid-19 has the potential to cause TTS, a rare side effect associated with blood clotting.